
ProQR Therapeutics N.V. (NASDAQ:PRQR – Free Report) – Equities research analysts at HC Wainwright cut their FY2026 earnings estimates for ProQR Therapeutics in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will post earnings per share of ($0.44) for the year, down from their previous forecast of ($0.43). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for ProQR Therapeutics’ Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.11) EPS and FY2028 earnings at ($0.33) EPS.
Other equities research analysts have also recently issued reports about the company. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday. Wall Street Zen upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 15th. Bank of America assumed coverage on ProQR Therapeutics in a research report on Thursday, August 20th. They set a “buy” rating and a $8.00 target price on the stock. Finally, Raymond James Financial restated a “strong-buy” rating on shares of ProQR Therapeutics in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.60.
Check Out Our Latest Analysis on PRQR
ProQR Therapeutics Stock Down 16.3%
Shares of NASDAQ:PRQR opened at $1.18 on Tuesday. ProQR Therapeutics has a 12 month low of $1.17 and a 12 month high of $2.48. The company has a 50-day moving average price of $1.56 and a 200 day moving average price of $1.67.
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. The business had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $4.30 million.
Institutional Trading of ProQR Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. Marshall Wace LLP bought a new position in ProQR Therapeutics in the third quarter worth approximately $1,860,000. RFG Advisory LLC boosted its position in ProQR Therapeutics by 236.8% during the 2nd quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 45,000 shares in the last quarter. Axiom Investment Management LLC purchased a new position in shares of ProQR Therapeutics in the 1st quarter valued at $53,000. Alpha Wealth Funds LLC purchased a new position in shares of ProQR Therapeutics in the 3rd quarter valued at $41,000. Finally, Walleye Capital LLC raised its position in shares of ProQR Therapeutics by 2.7% in the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock worth $984,000 after acquiring an additional 15,744 shares in the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V. is a biotechnology company developing RNA-based medicines for genetic diseases. Its research centers on Axiomer, a platform designed to make targeted changes to RNA using the body’s naturally occurring editing machinery. Founded in 2012 and based in Leiden, the Netherlands, ProQR initially focused on RNA therapies for inherited retinal disorders, including Usher syndrome and Leber congenital amaurosis. The company later broadened its emphasis to RNA editing and continues to develop potential treatments for genetic conditions.
Read More
- Five stocks we like better than ProQR Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
